G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
86 hedge funds and large institutions have $61.6M invested in G1 Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 31 increasing their positions, 17 reducing their positions, and 19 closing their positions.
140% more call options, than puts
Call options by funds: $4.23M | Put options by funds: $1.76M
82% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 17
58% more capital invested
Capital invested by funds: $39M → $61.6M (+$22.6M)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
1% less funds holding
Funds holding: 87 → 86 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.52M |
| 2 |
Millennium Management
New York
|
+$1.45M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.31M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.01M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$966K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.19M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.12M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.1M |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$1.02M |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$814K |
GTHX Hedge Fund Activity: Q1 2024 in Review
86 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q1 2024, worth a combined $61.6M — up 58% from $39M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of GTHX and 18 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 31 added.
The largest buyer was Goldman Sachs, adding an estimated $1.52M. The largest seller was Susquehanna International Group, cutting an estimated $2.19M.
- 86 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q1 2024, down from 87 in Q4 2023.
- Funds reported $61.6M of G1 Therapeutics, Inc. Common Stock stock for Q1 2024, up 58% quarter-over-quarter.
- 18 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q1 2024 and 19 closed out, a net change of -1 holder.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q1 2024 was Goldman Sachs, an estimated $1.52M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q1 2024 was Susquehanna International Group, an estimated $2.19M sold.
Based on aggregated 13F filings for Q1 2024.